Fapon is preparing to introduce its ProPrime II Taq DNA Polymerase and MeloScript III Reverse Transcriptase at ADLM 2026, positioning the AI-engineered enzymes as faster and more inhibitor-resistant components for PCR and RT-qPCR diagnostic workflows. The privately held in vitro diagnostics supplier will also showcase raw materials and bulk reagents intended to support manufacturers developing blood-based Alzheimer’s disease assays.
The products will be presented during the Association for Diagnostics and Laboratory Medicine meeting in Anaheim, California, from July 26 to July 30, alongside Fapon’s Shine i1000 and Shine i3000 chemiluminescence immunoassay analyzers. The combined display reflects a broader strategy that stretches from upstream antibodies and enzymes to bulk reagents, open instruments, assay development support and regional supply infrastructure.
The commercial opportunity is not simply about selling another polymerase or antibody. Fapon is attempting to occupy more of the diagnostic development chain, particularly where manufacturers face pressure to improve assay sensitivity, shorten amplification times, secure reliable raw materials and move emerging biomarkers into reproducible clinical products.
That proposition is timely. Molecular diagnostic developers continue to look for enzymes that can tolerate inhibitors, work with low-input samples and support faster thermal cycling. Alzheimer’s diagnostics, meanwhile, are moving toward blood-based biomarkers after regulatory clearances and new clinical guidance increased confidence that appropriately validated tests can play a meaningful role in the evaluation of patients with cognitive impairment.
Fapon’s products are components and development tools, however, rather than independently authorised clinical tests. Their ultimate value will depend on the performance of the finished assays developed by customers, including analytical validation, clinical validation, manufacturing consistency and regulatory clearance for clearly defined intended uses.
What do ProPrime II and MeloScript III add to Fapon’s molecular diagnostics portfolio?
Fapon describes ProPrime II as an AI-engineered Taq DNA polymerase designed for PCR and qPCR applications. According to company materials released around ADLM 2026, the enzyme uses an antibody-enabled hot-start mechanism intended to suppress polymerase activity at ambient temperatures before rapidly releasing activity during heating.
Hot-start control can be important for reducing non-specific amplification and primer-dimer formation during reaction preparation. This becomes particularly relevant in multiplex assays, low-copy-number detection and workflows in which reagents may spend extended periods at room temperature before entering a thermal cycler.
Fapon is also positioning ProPrime II for ultra-fast qPCR and direct amplification workflows with limited or no nucleic acid extraction. These applications place considerable demands on an enzyme because blood, transport media and other clinical matrices can contain substances that interfere with amplification.
The company’s earlier ProPrime Taq DNA Polymerase was marketed around rapid amplification, sensitivity and tolerance to inhibitors, including whole-blood samples. ProPrime II appears to be an upgraded generation intended to extend those characteristics, although Fapon has not publicly disclosed a complete comparative dataset showing how the new enzyme performs against its predecessor or widely used competing polymerases.
MeloScript III is a reverse transcriptase developed for RT-PCR and RT-qPCR workflows. Fapon says the enzyme remains active at temperatures of up to approximately 60 degrees Celsius, which could assist with RNA templates containing complex secondary structures or high guanine-cytosine content.
Higher-temperature reverse transcription may improve access to structured RNA regions, while strong inhibitor tolerance could support direct amplification approaches. The company is also promoting MeloScript III for low-input samples, an increasingly important requirement in infectious disease testing, oncology applications and other molecular assays where the available RNA concentration may be limited.
The central question for diagnostic manufacturers will be whether those claimed advantages remain consistent across different assay designs, sample matrices and production lots. Enzyme performance measured under selected laboratory conditions does not automatically translate into improved clinical sensitivity or specificity in a finished diagnostic product.
How much evidence has Fapon disclosed for the AI-engineered enzyme performance claims?
Fapon has said ProPrime II and MeloScript III were developed through an AI-assisted platform that predicts useful amino-acid mutations, models protein structure and combines computational design with laboratory screening. The company describes this as a closed loop between dry experiments and wet-laboratory validation.
This model is increasingly common across enzyme engineering and protein design. Computational systems can narrow the number of variants that need to be produced and tested, potentially accelerating the identification of enzymes with improved thermostability, inhibitor resistance or catalytic activity.
The use of artificial intelligence is not itself evidence that the resulting enzyme is better. Diagnostic manufacturers will require conventional performance data covering amplification efficiency, limit of detection, reproducibility, linearity, specificity, inhibitor tolerance, thermal stability and compatibility with commonly used buffers, probes and instruments.
For ProPrime II, useful comparative evidence would include cycle-threshold performance across low-copy samples, amplification time, resistance to haemoglobin and other inhibitors, multiplex compatibility and the frequency of non-specific products. For MeloScript III, manufacturers will want data on full-length complementary DNA synthesis, low-input RNA recovery, reaction efficiency at different temperatures and performance across diverse RNA targets.
Fapon has described the enzymes as being backed by proprietary intellectual property and freedom-to-operate analysis. That may reduce intellectual property concerns for customers incorporating the components into commercial assays, but it remains separate from technical validation, clinical utility and regulatory acceptance.
The ADLM demonstrations may therefore be most valuable as the beginning of customer evaluation rather than the end of product validation. Sample testing, side-by-side benchmarking and customised formulation work will determine whether the enzymes can win places in regulated diagnostic workflows.
Why are Fapon’s Alzheimer’s blood biomarker materials commercially relevant now?
The Alzheimer’s diagnostic environment has changed significantly following regulatory progress for blood-based tests. In May 2025, the United States Food and Drug Administration cleared Fujirebio Diagnostics’ Lumipulse G pTau217 and beta-amyloid 1-42 Plasma Ratio as an aid in detecting amyloid plaques associated with Alzheimer’s disease in adults aged 55 and older who show signs or symptoms of cognitive decline.
The clearance demonstrated that a blood-based in vitro diagnostic could enter the regulated United States market for a defined clinical role. It did not establish blood testing as a universal screening tool or a stand-alone diagnosis, but it gave assay developers a clearer regulatory precedent.
Roche Diagnostics subsequently received clearance for its Elecsys Phospho-Tau 181P Plasma assay, which is intended to help rule out amyloid pathology during the initial assessment of appropriate patients in primary care. Together, these products illustrate that different biomarkers and clinical-use models may be incorporated into the diagnostic pathway.
The Alzheimer’s Association has also issued evidence-based clinical guidance covering blood biomarkers in specialised care. The guideline evaluated p-tau217, percentage p-tau217, p-tau181, p-tau231 and the amyloid-beta 42 to amyloid-beta 40 ratio, while emphasising that test performance must meet defined accuracy thresholds and results should be interpreted within a comprehensive clinical assessment.
Fapon previously described its Alzheimer’s materials portfolio as covering p-tau217, p-tau181, amyloid-beta 40, amyloid-beta 42, glial fibrillary acidic protein, neurofilament light and APOE4-related materials. The company is offering raw materials and bulk reagents rather than a single branded, patient-facing test, allowing manufacturers to select biomarkers and develop assays for their chosen instrument platforms and intended uses.
This supplier position could benefit from the expansion of Alzheimer’s testing without requiring Fapon to commercialise every assay directly. Multiple manufacturers may need antibodies, antigens, calibrators, controls and bulk reagent formulations as they build products for specialty laboratories, hospital systems or decentralised testing pathways.
Why does supplying raw materials not guarantee a successful Alzheimer’s blood test?
Blood biomarker assay development is technically demanding because clinically relevant proteins may be present at low concentrations and can be affected by pre-analytical variables, matrix interference and differences between patient populations. A strong antibody pair or bulk reagent is only one part of a complete diagnostic system.
Developers must establish analytical sensitivity, precision, linearity, interference resistance, lot-to-lot consistency and stability. They must then demonstrate that the assay’s result reliably corresponds with an accepted reference standard, such as amyloid positron emission tomography, cerebrospinal fluid biomarkers or another clinically justified comparator.
The intended use also matters. A test designed to rule out amyloid pathology in primary care requires different thresholds and risk management from a confirmatory test used in a specialist memory clinic. False-positive and false-negative results can lead to inappropriate referrals, unnecessary procedures, delayed diagnoses or treatment decisions based on incomplete information.
Biomarker choice alone cannot resolve these issues. Two assays measuring p-tau217 may produce different results because of antibody specificity, calibration, signal detection, sample handling and statistical threshold selection. Manufacturers using Fapon’s materials will need to generate their own evidence for the finished product rather than relying on the general scientific reputation of a biomarker.
Fapon’s ISO 13485 manufacturing framework may support quality management and consistency, but certification does not establish the clinical performance of every assay created with its components. Regulatory responsibility ultimately remains with the developer that defines the intended use, completes validation and places the diagnostic product on the market.
Can Fapon’s one-stop IVD model reduce development risk for smaller manufacturers?
Fapon is presenting the Alzheimer’s portfolio within a larger service model that includes raw materials, bulk reagents, customised development, technology transfer and open-system instruments. This approach may appeal to manufacturers that lack extensive internal antibody discovery, enzyme engineering or reagent optimisation capabilities.
Using a single supplier for several development stages could shorten vendor qualification and improve coordination between raw materials, reagents and instrument settings. It may also help customers investigate performance problems without repeatedly transferring responsibility between unrelated component providers.
The Shine i1000 and Shine i3000 analyzers form part of this strategy. Fapon says the broader Shine i-Series supports more than 70 internally developed reagent assays and offers different throughput configurations. At ADLM 2026, live demonstrations will provide an opportunity to show how the company’s reagents interact with its open chemiluminescence platforms.
Open systems can give laboratories and diagnostic manufacturers greater assay flexibility than tightly closed platforms. They can also introduce additional validation and integration responsibilities because each reagent configuration may require optimisation, quality control and locally appropriate regulatory documentation.
Fapon’s value proposition will therefore depend on how much practical development work it can remove from customers. Access to applications scientists, troubleshooting support, reference methods, stability studies and documentation may be just as important as the underlying component catalogue.
How credible is Fapon’s expanding North American localisation strategy?
Fapon has gradually increased its physical presence in the United States. The company opened a research and development centre in Lexington, Massachusetts, in 2023 and has described the site as a base for enzyme innovation and collaboration within the Greater Boston biotechnology cluster.
Its public materials also reference a North American warehouse, regional technical personnel and local production capabilities. The localisation strategy is intended to reduce delivery times, improve technical communication and reassure customers concerned about supply continuity.
For North American diagnostic manufacturers, regional support can be commercially significant. Assay development frequently requires repeated sample evaluations, technical consultations, formulation adjustments and rapid replacement of components. A local team may respond more effectively than a remote sales operation working across large time-zone differences.
The depth of localisation will still need to be demonstrated. Customers will examine which products are genuinely manufactured in the United States, which are imported and stocked locally, how changes are controlled across production sites, and whether technical and quality teams can support regulatory inspections or complex manufacturing investigations.
Fapon’s presence at ADLM is consequently both a product showcase and a trust-building exercise. North American manufacturers are unlikely to change critical diagnostic raw materials solely because of exhibition claims. They will require performance evidence, supply agreements, quality documentation and confidence that the supplier can remain responsive throughout development and commercial scale-up.
What milestones will determine whether the ADLM 2026 showcase becomes commercially meaningful?
The immediate milestone will be independent customer evaluation of ProPrime II and MeloScript III. Detailed application notes, comparative datasets and successful use in customer-developed PCR or RT-qPCR products would provide stronger validation than general claims about AI-assisted engineering.
For the Alzheimer’s portfolio, progress will be measured by partnerships with assay manufacturers, completion of clinically validated reagent configurations and eventual regulatory submissions for finished diagnostics incorporating Fapon materials. The company has not announced that its ADLM showcase itself represents regulatory clearance for an Alzheimer’s test.
Fapon will also need to demonstrate that its upstream materials can support the precision required for blood biomarkers across multiple instrument platforms. This includes stable calibration, low background signal, reproducible measurement near clinical decision thresholds and reliable production at commercial scale.
The company’s broader commercial test is whether it can convert an unusually wide portfolio into a coherent service model. Supplying enzymes, antibodies, bulk reagents, controls and instruments creates cross-selling opportunities, but it also increases the need for disciplined quality management and specialised technical expertise across multiple diagnostic technologies.
Fapon’s ADLM 2026 presentation is therefore best understood as an infrastructure and capability announcement rather than a clinical breakthrough. The new enzymes may improve molecular assay development, and the Alzheimer’s reagents may help manufacturers enter a rapidly developing diagnostic field, but neither outcome is assured by the exhibition alone.
The most persuasive evidence will arrive after Anaheim, when customers begin benchmarking the enzymes, integrating the biomarker materials and deciding whether Fapon’s North American support model can meet the quality, validation and supply requirements of regulated diagnostic development.
